Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 1/2a Trial of PRO-1562 in Healthy Adults and Adults With Multiple Sclerosis and Chronic Optic Neuropathy
NCT07826689 is registered in ClinicalTrials.gov with Progentos Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Phase 1/2a Trial of PRO-1562 in Healthy Adults and Adults With Multiple Sclerosis and Chronic Optic Neuropathy
- Lead sponsor
- Progentos Therapeutics
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- October 31, 2026
- Completion date
- February 28, 2029
- Enrollment
- 160 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.